← Browse by Condition
Medical Condition

neuroendocrine carcinomas

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for neuroendocrine carcinomas sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neuroendocrine carcinomas Clinical Trials

How many clinical trials are currently recruiting for neuroendocrine carcinomas?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for neuroendocrine carcinomas, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neuroendocrine carcinomas?
neuroendocrine carcinomas research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neuroendocrine carcinomas clinical trial?
Eligibility criteria for neuroendocrine carcinomas trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Latin American Cooperative Oncology Group 1 trial
IDEAYA Biosciences 1 trial

Recruiting Clinical Trials

NCT07192991
Recruiting
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
Enrollment
200 pts
Location
Argentina, Brazil, M...
Sponsor
Latin American Cooperative Onc...
View Trial →
NCT07174583 Phase 1, Phase 2
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Enrollment
262 pts
Location
United States
Sponsor
IDEAYA Biosciences
View Trial →

Related Conditions

lung neuroendocrine carcinoma (1) small cell lung cancer (1) solid tumor show to express dll3 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology